Injectable hyaluronic acid microhydrogels for controlled release formulation of erythropoietin
Authors:
- 27 October 2006
- journal article
- research article
- Published by Wiley in Journal of Biomedical Materials Research Part A
- Vol. 80A (4) , 916-924
Abstract
An injectable hyaluronic acid (HA) microhydrogel was successfully developed as a novel drug carrier for controlled release formulation of protein drugs. HA hydrogels were prepared by the disulfide bond formation of thiolated HA (HA‐SH). EPO was loaded in situ during HA‐SH hydrogel preparation using an accelerating agent of sodium tetrathionate. The gelation time was drastically reduced from a day to 30 min when sodium tetrathionate was added for HA‐SH hydrogel preparation. In vitro release of EPO in PBS at 37°C showed that EPO was rapidly released for 3 days with an initial burst and then slowly up to 9 days from HA‐SH hydrogels. HA‐SH microhydrogels were prepared by the reactive spray drying of diluted HA‐SH precursor solution. The mean particle size was ∼2.3 μm and the water content after spray drying was ∼14%. Ellman's test showed that sodium tetrathionate contributed not only for rapid crosslinking reaction but also for the reduction of residual free thiol content in HA‐SH microhydrogels after spray drying. EPO recovery from HA‐SH microhydrogels after degradation with hyaluronidase SD was higher than 95%. The released EPO appeared to be intact from the analysis with RP‐HPLC. According to in vivo release test of EPO from HA‐SH microhydrogels in Sprague Dawley (SD) rats, elevated plasma concentration of EPO higher than 0.1 ng/mL, which is a critical minimal concentration for EPO efficacy, was maintained up to 7 days. There was no adverse effect during and after the in vivo tests. © 2006 Wiley Periodicals, Inc. J Biomed Mater Res, 2006Keywords
This publication has 18 references indexed in Scilit:
- Development of a novel sustained release formulation of recombinant human growth hormone using sodium hyaluronate microparticlesJournal of Controlled Release, 2005
- Clinical and Economic Impact of Epoetins in Cancer CarePharmacoEconomics, 2004
- A hydrogel prepared by in situ cross-linking of a thiol-containing poly(ethylene glycol)-based copolymer: a new biomaterial for protein drug deliveryBiomaterials, 2003
- Protein delivery from materials formed by self-selective conjugate addition reactionsJournal of Controlled Release, 2001
- Protein stability in controlled-release systemsNature Biotechnology, 2000
- Visual Evidence of Acidic Environment Within Degrading Poly(lactic-co-glycolic acid) (PLGA) MicrospheresPharmaceutical Research, 2000
- Recombinant human growth hormone poly(lactic-co-glycolic acid) microsphere formulation development1This manuscript is dedicated to the memory of Dr. Michael J. Cronin. Dr. Cronin was a brilliant endocrine scientist with an incredible ability to objectively evaluate any problem, no matter how complex. His spirit and knowledge contributed to the success of the work described herein and his wisdom continues to guide those of us fortunate enough to have known him.1Advanced Drug Delivery Reviews, 1997
- Controlled release of proteins from dextran hydrogelsJournal of Controlled Release, 1996
- New Methods of Drug DeliveryScience, 1990
- Prolonged Controlled-Release of Nafarelin, a Luteinizing Hormone-Releasing Hormone Analogue, from Biodegradable Polymeric Implants: Influence of Composition and Molecular Weight of PolymerJournal of Pharmaceutical Sciences, 1986